SMITH IAN F — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

SMITH IAN F has filed 4 SEC Form 4 filings across 3 companies in the last 90 days.

Profile

Ian F. Smith is the Chief Executive Officer of Stoke Therapeutics, Inc., a biotechnology company focused on RNA medicine and restoring protein expression. He has also held executive roles at Foghorn Therapeutics Inc. and Solid Biosciences Inc., contributing to advancements in genetic therapies.

Board memberships

• Stoke Therapeutics, Inc.
• Foghorn Therapeutics Inc.
• Solid Biosciences Inc.

Awards & honors

• Leadership in RNA medicine
• Development of zorevunersen for Dravet syndrome
• Executive roles in multiple biotech firms

Recent Transactions

Companies — Last 90 Days

• Solid Biosciences Inc. (SLDB) — 2 filings, last 2026-07-07
• Foghorn Therapeutics Inc. (FHTX) — 1 filings, last 2026-06-25
• Odyssey Therapeutics, Inc. (ODTX) — 1 filings, last 2026-05-12

Frequently Asked Questions

Who is SMITH IAN F?

Ian F. Smith is the Chief Executive Officer of Stoke Therapeutics, Inc., a biotechnology company focused on RNA medicine and restoring protein expression. He has also held executive roles at Foghorn Therapeutics Inc. and Solid Biosciences Inc., contributing to advancements in genetic therapies.…

How many SEC Form 4 filings has SMITH IAN F submitted recently?

4 primary Form 4 filings in the last 90 days, covering 3 companies.

Where can I see all of SMITH IAN F's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

• What is SEC Form 4?
• How to read insider buying signals
• Understanding Rule 10b5-1 trading plans
• Browse all insiders
• Most active insiders this week